Ifosfamide-induced nephrotoxicity: Mechanism and prevention

Cancer Research

Volumn 66, Issue 15, 2006, Pages 7824-7831

  Nissim, Itzhak ^a,b   Horyn, Oksana ^a   Daikhin, Yevgeny ^a   Nissim, Ilana ^a   Luhovyy, Bohdan ^a   Phillips, Peter C ^a   Yudkoff, Marc ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGMATINE; CARBON 13; CHLOROACETALDEHYDE; CYTOCHROME C OXIDASE; IFOSFAMIDE; MESNA; NICOTINAMIDE ADENINE DINUCLEOTIDE; PYRUVATE DEHYDROGENASE; PYRUVIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE (UBIQUINONE); TRICARBOXYLIC ACID; UBIQUINOL CYTOCHROME C REDUCTASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CITRIC ACID CYCLE; CONTROLLED STUDY; DRUG MECHANISM; KIDNEY CORTEX; MALE; MITOCHONDRION; NEPHROTOXICITY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; RAT;

ACETALDEHYDE; AGMATINE; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; DRUG INTERACTIONS; ELECTRON TRANSPORT COMPLEX I; IFOSFAMIDE; KIDNEY CORTEX; KIDNEY DISEASES; MALE; OXIDATIVE PHOSPHORYLATION; RATS;

EID: 33747872304     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1043     Document Type: Article

References (44)

1. Wagner T. Ifosfamide clinical pharmacokinetics. Clin Pharmacokinet 1994;26:439-56.
2. Fleming RA. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacology 1997;17:5146-54.
3. Skinner R. Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol 2003;41:190-7.
4. Goren MP, Wright RK, Horowitz ME, Pratt CB. Ifosfamide-induced subclinical tubular nephrotoxicity despite MESNA. Cancer Treat Rep 1987;71:127-30.
5. Friedlaender MM, Haviv YS, Rosenmann E, Peylan-Ramu N. End-stage renal interstitial fibrosis in an adult ten year after ifosfamide therapy. Am J Nephrol 1998;18:131-3.
6. Stohr W, Paulides M, Bielack S, et al. Ifosfamide-injduced nephrotoxicity in 593 sarcoma patients: A report from the late effects surveillance system. Pediatr Blood Cancer 2006; Epub ahead of print.
7. Prasad VK, Lewis IJ, Aparicio SR, et al. Progressive glomerular toxicity of ifosfamide in children. Med Pediatr Oncol 1996;27:149-55.
8. Nissim I, Weinberg JM. Glycine attenuates maleate or ifosfamide induced Fanconi syndrome in rats. Kidney Int 1996;49:684-95.
9. Loebstein R, Atanackovic G, Bishai R, et al. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharmacol 1999;39:454-61.
10. Springate JE. Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo. J Appl Toxicol 1997;17:75-9.
11. Huang Z, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 2000;59:961-72.
12. Aleksa K, Matsell D, Krausz K, Gelboin H, Ito S, Koren G. Cytochrome P450 3A and 2B6 in the developing kidney: implication for ifosfamide nephrotoxicity. Pediatr Nephrol 2005;20:872-85.
13. Ghosh SS, Basu AK, Ghosh S, et al. Renal and hepatic family 3A cytochrome P450 in spontaneously hypertensive rats. Biochem Pharmacol 1995;50:49-54.
14. 15N. Am J Physiol 2002;283:1123-34.
15. Nissim I, Daikhin Y, Nissim I, et al. Agmatine stimulates hepatic fatty acid oxidation: a possible mechanism for upregulation of ureagenesis. J Biol Chem 2006;28:8486-96.
16. Triepels RH, Van Den Heuvel LP, Trijbels JM, et al. Respiratory chain complex I deficiency. Am J Med Genet 2001;106:37-45.
17. Ernst-Bernhard K, Margaret MS, Morgan PG, Hoppel CL. Mitochondrial oxidative phosphorylation is defective in the long-lived mutant clk-1. J Biol Chem 2004;279:54479-86.
18. Adam-Vizi V. Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-electron transport chain sources. Antioxid Redox Signal 2005;7:1140-9.
19. Weinberg JM, Venkatachalam MA, Roeser NF, Nissim I. Mitochondrial dysfunction during hypoxia/reoxygenation and its correction by anaerobic metabolism of citric acid cycle intermediates. Proc Natl Acad Sci U S A 2000;97:2826-31.
20. Grigorieff N. Structure of the respiratory NADH:ubiquinone oxidoreductase (COMPLEX I). Curr Opin Struct Biol 1999;9:476-83.
21. 15N- labeled arginine. Biochem J 2005;388:419-25.
22. Satriano J, Kelly CJ, Blantz RC. An emerging role for agmatine. Kidney Int 1999;56:1252-3.
23. Gerhard JM, Kribben B, Keinen A, Schroder D, Bruss M, Gothert M. Intestinal tumor and agmatine (decarboxylated arginine). Cancer 2004;101:858-68.
24. Whitehouse S. Cooper RH, Randle PJ. Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids. Biochem J 1974;141:761-74.
25. Stacpoole PW, Nagaraja NV, Hutson AD. Efficacy of dichloroacetate as a lactate-lowering drug. J Clin Pharmacol 2003;43:683-91.
26. Chance B, Williams GR. A simple and rapid assay of oxidative phosphorylation. Nature 1955;175:1120-1.
27. Birch-Machin MA, Briggs HL, Saborido AA, Bindoff LA, Turnbull DM. An evaluation of the measurement of the activities of complexes I-IV in the respiratory chain of human skeletal muscle mitochondria. Biochem J 1994;51:35-42.
28. Kaijser GP, Beijnen JH, Jeunink EL, et al. Determination of chloroacetaldehyde, a metabolite of oxazaphosphorine cytostatic drugs, in plasma. J Chromatogr 1993;614:253-9.
29. Altman PL, Dittmer DS, editors. Biology data book. Washington (District of Columbia): Federation of American Societies for Experimental Biology; 1964. pp. 401-3.
30. Goren MP, Wright RK, Pratt CB, Pell FE. Dechloroethylation of ifosfamide and neurotoxicity. Lancet 1986;2:1219-20.
31. Fiermonte G, Dolce V, Arrigoni R, Runswick MJ, Walker JE, Palmieri L. Organization and sequence of the gene for the human mitochondrial dicarboxylate carrier: evolution of the carrier family. Biochem J 1999;344:953-60.
32. Krebs HA, Veech RL. Equilibrium relations between pyridine nucleotides and adenine nucleotides and their roles in the regulation of metabolic processes. Adv Enzyme Regul 1969;7:397-413.
33. Weinberg JM, Venkatachalam MA, Roeser NF, et al. Anaerobic and aerobic pathways for salvage of proximal tubules from hyporia-induced mitochondrial injury. Am J Physiol 2000;279:F927-43.
34. Robert AH, Bowker-Kinley MM, Huang B, Wu P. Regulation of the activity of the pyruvate dehydrogenase complex. Adv Enzyme Regul 2002;42:249-59.
35. Bruggemann SK, Radike K, Braasch K, et al. Chloroacetaldehyde: mode of antitumor action of the ifosfamide metabolite. Cancer Chemother Pharmacol 2006;57:349-56.
36. 2+-signaling by chloroacetaldehyde: a possible cause for chronic ifosfamide nephrotoxicity. Kidney Int 2005;68:2029-41.
37. Schwerdt G, Gordjani N, Benesic A, et al. Chloroacetaldehyde and acrolein-induced death of human proximal tubule cells. Pediatr Nephrol 2006;21:60-7.
38. Sood C, O'Brien PJ. Molecular mechanisms of chloroacetaldehyde-induced cytotoxicity in isolated rat hepatocytes. Biochem Pharmacol 1993;46:1621-6.
39. Dubourg L, Michoudet C, Cochat P, Baverel G. Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide. J Am Soc Nephrol 2001;12:1615-23.
40. Rossignol R, Faustin B, Rocher C, Malgat M, Mazat JP, Letellier T. Mitochondrial threshold effects. Biochem J 2003;370:751-62.
41. Salvi M, Battaglia V, Mancon M, et al. Agmatine is transported into liver mitochondria by a specific electrophoretic mechanism. Biochem J 2006;396:337-45.
42. Grillo MA, Colmbatto S. Metabolism and function in animal tissues of agmatine, a biogenic amine formed from arginine. Amino Acids 2004;26:3-8.
43. Papa S, Scacco S, Sardanelli AM, et al. Complex I and cAMP cascade in human physiopathology. Biosci Rep 2002;22:3-16.
44. Mayeur C, Veuillet G, Michaud M, Raul F, Blottiere HM, Blachier F. Effect of agmatine accumulation in human colon carcinoma cells on polyamine metabolism, DNA synthesis and cell cycle. Biochim Biophys Acta 2005;1745:111-23.